|
1
|
Tsukihara H, Nakagawa F, Sakamoto K,
Ishida K, Tanaka N, Okabe H, Uchida J, Matsuo K and Takechi T:
Efficacy of combination chemotherapy using a novel oral
chemotherapeutic agent, TAS-102, together with bevacizumab,
cetuximab, or panitumumab on human colorectal cancer xenografts.
Oncol Rep. 33:2135–2142. 2015.PubMed/NCBI
|
|
2
|
Wang H, Zhang L, Yang X, Jin Y, Pei S,
Zhang D, Zhang H, Zhou B, Zhang Y and Lin D: PUMA mediates the
combinational therapy of 5-FU and NVP-BEZ235 in colon cancer.
Oncotarget. 6:14385–14398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang N, Yin Y, Xu SJ and Chen WS:
5-Fluorouracil: Mechanisms of resistance and reversal strategies.
Molecules. 13:1551–1569. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xi Y, Formentini A, Nakajima G, Kornmann M
and Ju J: Validation of biomarkers associated with 5-fluorouracil
and thymidylate synthase in colorectal cancer. Oncol Rep.
19:257–262. 2008.PubMed/NCBI
|
|
6
|
Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y,
Li J and Lou L: YN968D1 is a novel and selective inhibitor of
vascular endothelial growth factor receptor-2 tyrosine kinase with
potent activity in vitro and in vivo. Cancer Sci. 102:1374–1380.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Zhao X, Chen L, Guo H, Lv F, Jia K,
Yv K, Wang F, Li C, Qian J, et al: Safety and pharmacokinetics of
novel selective vascular endothelial growth factor receptor-2
inhibitor YN968D1 in patients with advanced malignancies. BMC
Cancer. 10:5292010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maehata T, Taniguchi H, Yamamoto H, Nosho
K, Adachi Y, Miyamoto N, Miyamoto C, Akutsu N, Yamaoka S and Itoh
F: Transcriptional silencing of Dickkopf gene family by CpG island
hypermethylation in human gastrointestinal cancer. World J
Gastroenterol. 14:2702–2714. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ebert MP, Tänzer M, Balluff B,
Burgermeister E, Kretzschmar AK, Hughes DJ, Tetzner R, Lofton-Day
C, Rosenberg R, Reinacher-Schick AC, et al: TFAP2E-DKK4 and
chemoresistance in colorectal cancer. N Engl J Med. 366:44–53.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baehs S, Herbst A, Thieme SE, Perschl C,
Behrens A, Scheel S, Jung A, Brabletz T, Göke B, Blum H and Kolligs
FT: Dickkopf-4 is frequently down-regulated and inhibits growth of
colorectal cancer cells. Cancer Lett. 276:152–159. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mandecki W, Mollison KW, Bolling TJ,
Powell BS, Carter GW and Fox JL: Chemical synthesis of a gene
encoding the human complement fragment C5a and its expression in
Escherichia coli. Proc Natl Acad Sci USA. 82:3543–3547. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Swartz JE, Pothen AJ, Stegeman I, Willems
SM and Grolman W: Clinical implications of hypoxia biomarker
expression in head and neck squamous cell carcinoma: A systematic
review. Cancer Med. 4:1101–1016. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koukourakis MI, Giatromanolaki A,
Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC and Harris
AL: Hypoxia inducible factor (HIF-1a and HIF-2a) expression in
early esophageal cancer and response to photodynamic therapy and
radiotherapy. Cancer Res. 61:1830–1832. 2001.PubMed/NCBI
|
|
15
|
Pendás-Franco N, García JM, Peña C, Valle
N, Pálmer HG, Heinäniemi M, Carlberg C, Jiménez B, Bonilla F, Muñoz
A and González-Sancho JM: DICKKOPF-4 is induced by TCF/beta-catenin
and upregulated in human colon cancer, promotes tumour cell
invasion and angiogenesis and is repressed by 1alpha,
25-dihydroxyvitamin D3. Oncogene. 27:4467–4477. 2008. View Article : Google Scholar : PubMed/NCBI
|
